
Spexis provides business update and announces financial results for the first half of 2023
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC) Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin® program …